AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27933698
Drug: Sofosbuvir plus
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir plus ribavirin therapy
Trial: 25938158
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine at a dose of 0.2 μg/kg.h for 12 hours
Trial: 25938158
Drug: Intravenous normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline for 12 hours
Trial: 23362991
Drug: Specific psychological
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific psychological intervention (6 sessions) along with fluoxetine
Trial: 23362991
Drug: Non-specific psychological
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-specific psychological intervention (6 sessions) along with fluoxetine
Trial: 18778179
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg/day) for 16 weeks
Trial: 16138713
Drug: Slow-release fluvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release fluvastatin 80 mg/day
Trial: 16138713
Drug: Immediate-release fluvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release fluvastatin 40 mg/day
Trial: 11876598
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (budesonide aqueous nasal spray: 128 microg b.i.d.)
Trial: 7649341
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg dropropizine orally, three times daily for 3 days
Trial: 7649341
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg levodropropizine orally, three times daily for 3 days
Trial: 2668428
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g once a day
Trial: 2668428
Drug: Cefotaxime 2
RxNorm normalized name: cefotaxime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 2 g every 4 h
Trial: 27886078
Drug: 500 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 µg vitamin B12 and 400 µg folic acid daily
Trial: 22314083
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D supplement (1000 IU cholecalciferol/day)
Trial: 12803583
Drug: Methylprednisolone (MP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP, 15 mg kg‐1, n = 12)
Trial: 12803583
Drug: Tirilazad mesylate
RxNorm normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad mesylate (TM, 10 mg kg‐1, n = 12)
Trial: 10372428
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg.kg‐1)
Trial: 2102704
Drug: N-acetyl-L-cysteine
RxNorm normalized name: N-acetyl-L-cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetyl-L-cysteine
Trial: 1752851
Drug: Diphenhydramine 25‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 25‐50 mg (N = 9)
Trial: 30027612
Drug: Daily application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application of the antiaging cream (0.1% RAL, GGO, Pre-tocopheryl) for 8 weeks
Trial: 30027612
Drug: Three sequential
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three sequential glycolic acid (GA) peels (20%, 50%, and 70%) every 2-3 weeks
Trial: 22471260
Drug: PLDLA implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLDLA implant arthroplasty
Trial: 20595906
Drug: Ritonavir 200
RxNorm normalized name: lopinavir-ritonavir 200 mg-50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 200 mg
Trial: 17482177
Drug: Microdose GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microdose GnRH agonist flare (ML)
Trial: 17482177
Drug: GnRH antagonist/letrozole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH antagonist/letrozole (AL)
Trial: 9524897
Drug: Acetylcholine (ACH)
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine (ACH) infusion
Trial: 28029445
Drug: E10030 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E10030 1.5 mg in combination with ranibizumab 0.5 mg
Trial: 28029445
Drug: E10030 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E10030 0.3 mg in combination with ranibizumab 0.5 mg
Trial: 28029445
Drug: Sham in
RxNorm normalized name: Amersham Indium (111In) Oxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham in combination with ranibizumab 0.5 mg (anti-VEGF monotherapy)
Trial: 21843430
Drug: Free water
RxNorm normalized name: MENTHOL 2.5 mg ORAL LOZENGE [Halls Sugar Free Watermelon]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free water intake (treatment group)
Trial: 16636167
Drug: Drugs for
RxNorm normalized name: DRUGS FOR CONSTIPATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs for atrial fibrillation
Trial: 15658648
Drug: Shexiang Baoxin
RxNorm normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shexiang Baoxin pill (SBP)
Trial: 9032192
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (800 mg twice daily for 2 weeks)
Trial: 9032192
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (30 mg daily for 2 weeks)
Trial: 2891867
Drug: Topical indometacin
RxNorm normalized name: indometacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indometacin
Trial: 2891867
Drug: Beta-blocker and
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker and pilocarpine 2%
Trial: 26758700
Drug: α‐MSH levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α‐MSH levels in obese children (1194±865 ng/mL)
Trial: 26758700
Drug: AgRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AgRP levels in obese children (828±417 ng/mL)
Trial: 24313633
Drug: Sertraline 100
RxNorm normalized name: sertraline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 100 mg daily for 4 weeks (after initial 8 weeks of 50 mg)
Trial: 24313633
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg daily for 8 weeks, continued for 4 weeks
Trial: 24313633
Drug: Sertraline 100
RxNorm normalized name: sertraline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 100 mg daily for 4 weeks
Trial: 17234108
Drug: XP-828L 5
RxNorm normalized name: XP-102
DrugBank: XP-102 (DB18780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP-828L 5 g/d for 56 days
Trial: 15469666
Drug: Quetiapine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (150 mg)
Trial: 10648333
Drug: MST 20
RxNorm normalized name: MST 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MST 20 mg 12 hourly
Trial: 10648333
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate 10 mg IM 6 hourly
Trial: 6149758
Drug: +cyanidanol-3 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +cyanidanol-3 (2 g daily, 500 mg qds)
Trial: 3780692
Drug: Spinal blockade
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal blockade with 0.5% bupivacaine (3 ml)
Trial: 3780692
Drug: Epidural blockade
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blockade with 0.5% bupivacaine (19 ml)
Trial: 30045422
Drug: Oral Melissa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Melissa officinalis (MO) 3 g/d
Trial: 20531162
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy (PT) intervention consisting of eight 90‐min sessions with 30 mins of each session devoted to PT, focusing on truncal and limb isodynamic strengthening and education.
Trial: 20531162
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy (PT) intervention
Trial: 17713476
Drug: Raltegravir (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (single-dose escalation study)
Trial: 17713476
Drug: Raltegravir (multiple-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (multiple-dose escalation study)
Trial: 17713476
Drug: Raltegravir (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (single-dose female study)
Trial: 17149454
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (1 hour instructional session, followed by 4 weeks of daily home practice)
Trial: 12511185
Drug: Insulin-sensitive (IS)
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-sensitive (IS) patients
Trial: 12511185
Drug: Insulin-resistant (IR)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-resistant (IR) patients
Trial: 7859960
Drug: No prior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prior intravenous sedation (second phase)
Trial: 2680158
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg three times daily)
Trial: 2680158
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and dipyridamole (325 mg and 75 mg, respectively, three times daily)
Trial: 2680158
Drug: All aspirin
RxNorm normalized name: CAREALL Aspirin 81mg Chewable Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All aspirin groups combined
Trial: 2680158
Drug: All aspirin
RxNorm normalized name: CAREALL Aspirin 81mg Chewable Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All aspirin groups for grafts to vessels ≤ 2.0 mm
Trial: 2680158
Drug: All aspirin
RxNorm normalized name: CAREALL Aspirin 81mg Chewable Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All aspirin groups for grafts to vessels > 2.0 mm
Trial: 30282861
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g butter (B10)
Trial: 30282861
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g butter (B20)
Trial: 30282861
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g butter (B40)
Trial: 30282861
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g butter (control)
Trial: 26440437
Drug: IV tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tramadol (2 mg/kg, 3 mL)
Trial: 26440437
Drug: Subcutaneous infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration with tramadol (2 mg/kg, 3 mL)
Trial: 18544622
Drug: 1,500 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 IU daily
Trial: 18544622
Drug: 10,500 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,500 IU once weekly
Trial: 15872124
Drug: Lidocaine 20
RxNorm normalized name: lidocaine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 20 mg plus metoclopramide 10 mg iv
Trial: 15872124
Drug: Lidocaine 20
RxNorm normalized name: lidocaine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 20 mg iv
Trial: 15385009
Drug: Early intravenous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intravenous placement (30 seconds after loss of lid reflex)
Trial: 15385009
Drug: Late intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late intravenous placement (120 seconds after loss of lid reflex)
Trial: 10073791
Drug: Niacin and
RxNorm normalized name: My Favorite Niacin and Inositol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin and etofibrate combination
Trial: 394281
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (Voltarol) 25 mg t.d.s. for 2 weeks
Trial: 394281
Drug: Indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 mg t.d.s. for 2 weeks
Trial: 30107043
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg, twice daily for 52 weeks
Trial: 30107043
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily for 52 weeks
Trial: 25231565
Drug: Active bioresonance
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active bioresonance therapy
Trial: 10380428
Drug: Antifungal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal drugs
Trial: 6751374
Drug: Topical benzimidazole
RxNorm normalized name: benzimidazole
DrugBank: Benzimidazole (DB02962)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzimidazole sunscreen cream
Trial: 28126898
Drug: Atosiban (6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (6.75 mg)
Trial: 28126898
Drug: Fenoterol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (40 μg)
Trial: 26820158
Drug: Vitamin E,
RxNorm normalized name: GRx Vitamin E, topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin E, C, A, and N-acetylcysteine daily (treatment group)
Trial: 17466492
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER 3 mg
Trial: 17265397
Drug: Engineered sharps
RxNorm normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engineered sharps injury prevention device (ESIPD) - intravenous (IV) catheter stylet with a safety-engineered feature (retractable protection shield)
Trial: 12413985
Drug: Tibolone, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone, 2.5 mg/d for 4 months
Trial: 10220653
Drug: Neo-Temp luting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-Temp luting agent
Trial: 10220653
Drug: Temp Bond
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temp Bond luting agent
Trial: 10220653
Drug: Provilink luting
RxNorm normalized name: MULTIVIT/OPHTH AREDS2/LUTE/ZEAX CHEW TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provilink luting agent
Trial: 27015966
Drug: Panic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panic and Smoking Reduction Treatment (PSRT) + d-cycloserine (DCS)
Trial: 27015966
Drug: Panic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panic and Smoking Reduction Treatment (PSRT) + placebo
Trial: 22622911
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections with local anesthetic and steroids
Trial: 22622911
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections (unspecified)
Trial: 16075363
Drug: Adjuvant oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant oral clodronate (1.6 g/day) for 3 years
Trial: 10189133
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 10 mg twice daily
Trial: 10189133
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) plus octreotide 150 microg (subcutaneously thrice daily)
Trial: 1955654
Drug: Pefloxacin 400
RxNorm normalized name: pefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 400 mg every 12 hours for 3 days (first dose 800 mg)
Trial: 6814284
Drug: Intranasal immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal immunotherapy with Glu‐Rye (10-week course)
Trial: 6814284
Drug: Intranasal immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal immunotherapy with Glu‐Rye
Trial: 19139439
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (15 weeks) followed by surgery (arm A)
Trial: 19139439
Drug: Chemotherapy (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (12 weeks) followed by chemoradiotherapy (3 weeks) followed by surgery (arm B)
Trial: 9564208
Drug: Fluoxetine (N
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (N = 8)
Trial: 9564208
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and Placebo (combined sample of 17 cocaine-abusing depressed alcoholics)
Trial: 363434
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release oxprenolol (SRO) once daily
Trial: 363434
Drug: Conventional oxprenolol
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional oxprenolol (CO) once daily
Trial: 363434
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing of SRO
Trial: 363434
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing of SRO
Trial: 17719468
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg once daily for 6 months followed by 6 months of single-blind Val in both groups
Trial: 15064638
Drug: Empirical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical therapy based on baseline culture data
Trial: 11478829
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine (0.45 g kg(‐1)day(‐1)) for eight weeks
Trial: 7798804
Drug: Plasminogen activation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasminogen activation using streptokinase in blood suspensions of diabetic patients
Trial: 7798804
Drug: Plasminogen activation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasminogen activation using streptokinase in blood suspensions of healthy subjects
Trial: 31331583
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of Panax Ginseng twice daily for four weeks
Trial: 28364587
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy (CBGT) for OCD, involving family members in two sessions, 12 sessions total.
Trial: 16408442
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group treated as same as adult patients with diabetes mellitus
Trial: 15329366
Drug: saquinavir/ritonavir 1000/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saquinavir/ritonavir 1000/100 mg twice-daily
Trial: 15329366
Drug: saquinavir/ritonavir 2000/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saquinavir/ritonavir 2000/100 mg once-daily
Trial: 15329366
Drug: saquinavir/ritonavir 1600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saquinavir/ritonavir 1600/100 mg once-daily
Trial: 10934984
Drug: Various β-Blockers
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various β-Blockers
Trial: 1286547
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg once daily for 4 weeks)
Trial: 4036846
Drug: High P/S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High P/S ratio diet with high cholesterol (1,000 mg/day)
Trial: 4036846
Drug: High P/S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High P/S ratio diet with low cholesterol (300 mg/day)
Trial: 4036846
Drug: Low P/S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low P/S ratio diet with high cholesterol (1,000 mg/day)
Trial: 4036846
Drug: Low P/S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low P/S ratio diet with low cholesterol (300 mg/day)
Trial: 30774388
Drug: Benralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 30 mg every 4 weeks (Q4W)
Trial: 30661249
Drug: Benralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 30 mg every 8 weeks (Q8W)
Trial: 22184611
Drug: Ropivacaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (20 mL of different concentrations)